NASDAQ:SRPT
Sarepta Therapeutics Stock News
$130.83
-0.550 (-0.419%)
At Close: May 20, 2024
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 29'th Mar 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on March 29, 2024 that were previously ap
Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 29'th Mar 2024
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
08:00am, Wednesday, 13'th Mar 2024
Regenxbio reported some favorable data from a phase 1 clinical trial. Sarepta Therapeutics has a medicine on the market for the same target.
Got $1,000? Buy These Hot Growth Stocks Before They Take Off.
05:45am, Friday, 08'th Mar 2024
Biopharma company Sarepta Therapeutics is on the verge of reaching sustained profits. Last year was miserable for Enphase Energy, and this year isn't likely to be much better thanks to the tepid deman
Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst
09:47am, Monday, 04'th Mar 2024
Sarepta Therapeutics is trying to widen its market for Elevidys. Regulators should deliver a verdict in early March.
Sarepta (SRPT) Q4 Earnings Beat Estimates, Revenues Up Y/Y
01:36pm, Thursday, 29'th Feb 2024
Sarepta's (SRPT) Q4 earnings and sales beat estimates on the back of strong sales for recently-approved DMD gene therapy Elevidys.
Sarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call Transcript
07:33pm, Wednesday, 28'th Feb 2024
Sarepta Therapeutics, Inc. (SRPT) Q4 2023 Earnings Call Transcript
Sarepta Therapeutics (SRPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
07:01pm, Wednesday, 28'th Feb 2024
The headline numbers for Sarepta Therapeutics (SRPT) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall
Is It Too Late to Buy Sarepta Therapeutics Stock?
07:15am, Wednesday, 28'th Feb 2024
Sarepta Therapeutics faced some issues last year, but it earned approval for an important medicine. The biotech is on the verge of another key regulatory nod that should help improve its financial res
Why Earnings Season Could Be Great for Sarepta Therapeutics (SRPT)
09:51am, Tuesday, 27'th Feb 2024
Sarepta Therapeutics (SRPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Sarepta (SRPT) to Report Q4 Earnings: Will It Beat Estimates?
12:25pm, Wednesday, 21'st Feb 2024
Investors' focus will likely be on Sarepta's (SRPT) product sales of its recently-approved DMD gene therapy when it reports fourth-quarter earnings.
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
08:30am, Wednesday, 21'st Feb 2024
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2023 financial results
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
11:06am, Tuesday, 20'th Feb 2024
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up
07:31am, Monday, 19'th Feb 2024
Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.
Sarepta Therapeutics (SRPT) Moves 7.8% Higher: Will This Strength Last?
04:31am, Monday, 19'th Feb 2024
Sarepta Therapeutics (SRPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the n